Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoantigen DNA Vaccine with Nivolumab, Ipilimumab, and PROSTVAC in mHSPC
NCT03532217Phase 1Completed
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2018
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 1, open-label trial in prostate cancer (PCa), sponsored by Washington University School of Medicine. Started Sep 2018; status: completed.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03532217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532217.